Login to Your Account

House committee shoots down IPR carve-out for biopharma

By Mari Serebrov
Regulatory Editor

Friday, June 12, 2015
Trade agreements, worry about sending the wrong message and fears of escalating drug prices could end biopharma's hopes of an exemption from the inter partes review (IPR) process, which can play havoc with drug and device patents and stock value.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription